AN2 Therapeutics ANTX

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.02 (+1.55%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

Business overview of AN2 Therapeutics (ANTX)
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.

Key Insights

Critical company metrics and information

  • Latest Closing Price

    $1.31

  • Market Cap

    $39.14 Million

  • Price-Earnings Ratio

    -0.66

  • Total Outstanding Shares

    29.88 Million Shares

  • Total Employees

    36

  • Dividend

    $0.66 Per Share Quarterly

  • IPO Date

    March 25, 2022

  • SIC Description

    Pharmaceutical Preparations

  • Primary Exchange

    NASDAQ

  • Type

    Common Stock

  • Headquarters

    1800 el camino real, suite d, Menlo park, CA, 94027

  • Homepage

    https://www.an2therapeutics.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Financing Activities, Continuing$51,000
Net Cash Flow From Investing Activities, Continuing$61.89 Million
Net Cash Flow$888,000
Net Cash Flow From Operating Activities, Continuing$-61.05 Million
Net Cash Flow, Continuing$888,000
Net Cash Flow From Investing Activities$61.89 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Basic Earnings Per Share$-1.99
Basic Average Shares$31.88 Million
Income/Loss From Continuing Operations Before Tax$-60.70 Million
Revenues$0
Other Operating Expenses$17.00 Million
Net Income/Loss Attributable To Noncontrolling Interest$34,000

Comprehensive Income

October 1, 2023 to September 30, 2024
MetricValue
Comprehensive Income/Loss Attributable To Parent$-60.46 Million
Comprehensive Income/Loss$-60.46 Million
Other Comprehensive Income/Loss$-12.51 Million
Comprehensive Income/Loss Attributable To Noncontrolling Interest$0

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Current Assets$97.69 Million
Liabilities$10.02 Million
Noncurrent Liabilities$0
Equity$87.67 Million
Other Current Liabilities$6.20 Million
Liabilities And Equity$97.69 Million

Historical Dividends

Current dividend: $0.66 Per Share Quarterly
Announcement DatePayment DateRecord DateAmountFrequency
Apr 2, 2018May 1, 2018Apr 15, 2018$0.65625Quarterly
Sep 28, 2017Feb 1, 2018Jan 15, 2018$0.65625Quarterly
Sep 28, 2017Nov 1, 2017Oct 15, 2017$0.65625Quarterly
Jan 11, 2017Aug 1, 2017Jul 15, 2017$0.6562Quarterly
Jan 11, 2017May 1, 2017Apr 15, 2017$0.65625Quarterly
Dec 30, 2016Feb 1, 2017Jan 15, 2017$0.65625Quarterly

Recent Headlines From The Web

Latest news, press releases, and media coverage about ANTX from trusted financial sources
    All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

    ⓒ 2025 Financhle. All Rights Reserved.